No significant strengths identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ALKSAlkermes plc | 4.98B | 30.10 | 21.05 | -5.25% | 16.37% | 13.28% | 0.01% | 0.04 |
| ADMAADMA Biologics, Inc. | 3.71B | 15.57 | 19.22 | 65.15% | 42.87% | 48.57% | 2.97% | 0.24 |
| UTHRUnited Therapeutics Corporation | 21.99B | 503.90 | 18.09 | 10.61% | 41.94% | 18.81% | 4.73% | |
| PCSAProcessa Pharmaceuticals, Inc. | 114.71M | 2.17 | -0.56 | -221.71% | 0.04 | |||
| UNCYUnicycive Therapeutics, Inc. | 144.49M | 6.93 | -1.24 | -100% | -89.15% | 0.10 | ||
| PTHSPelthos Therapeutics Inc. | 85.29M | 26.36 | -1.95 | -318.41% | -40.48% | |||
| MISTMilestone Pharmaceuticals Inc. | 145.64M | 1.71 | -2.55 | -100% | -282.97% | 4.17 | ||
| AMRNAmarin Corporation plc | 5.74B | 13.80 | -3.45 | -25.51% | -38.01% | -18.78% | 0.02 |
Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 |
| Revenue Growth % | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin % | - | - | - |
| Gross Profit Growth % | - | - | - |
| Operating Expenses | 2.32M | 6.86M | 7.57M |
| OpEx % of Revenue | - | - | - |
| Selling, General & Admin | 1.93M | 4.28M | 6.39M |
| SG&A % of Revenue | - | - | - |
| Research & Development | 391.73K | 2.58M | 1.18M |
| R&D % of Revenue | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 |
| Operating Income | -2.32M | -6.86M | -7.57M |
| Operating Margin % | - | - | - |
| Operating Income Growth % | - | -196.02% | -10.33% |
| EBITDA | -2.32M | -6.86M | -7.17M |
| EBITDA Margin % | - | - | - |
| EBITDA Growth % | - | -196.02% | -4.47% |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 |
| EBIT | -2.32M | -6.86M | -7.17M |
| Net Interest Income | -140.43K | -518.51K | -786.39K |
| Interest Income | 0 | 0 | 0 |
| Interest Expense | 140.43K | 518.51K | 786.39K |
| Other Income/Expense | -140.43K | -518.51K | -383.89K |
| Pretax Income | -2.46M | -7.38M | -7.96M |
| Pretax Margin % | - | - | - |
| Income Tax | 0 | 0 | 0 |
| Effective Tax Rate % | 100% | 100% | 100% |
| Net Income | -2.46M | -7.38M | -7.96M |
| Net Margin % | - | - | - |
| Net Income Growth % | - | -200.2% | -7.78% |
| Net Income (Continuing) | -2.46M | -7.38M | -7.96M |
| Discontinued Operations | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| EPS (Diluted) | -4.26 | -12.80 | -13.54 |
| EPS Growth % | - | -200.47% | -5.78% |
| EPS (Basic) | -4.26 | -12.80 | -13.54 |
| Diluted Shares Outstanding | 576.75K | 576.75K | 587.62K |
| Basic Shares Outstanding | 576.75K | 576.75K | 587.62K |
| Dividend Payout Ratio | - | - | - |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Total Current Assets | 55.07K | 96.39K | 1.37M |
| Cash & Short-Term Investments | 55.07K | 96.39K | 513.44K |
| Cash Only | 55.07K | 96.39K | 513.44K |
| Short-Term Investments | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 40.4K |
| Days Sales Outstanding | - | - | - |
| Inventory | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - |
| Other Current Assets | 0 | 0 | 750K |
| Total Non-Current Assets | 0 | 0 | 0 |
| Property, Plant & Equipment | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - |
| Goodwill | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 |
| Total Assets | 55.07K | 96.39K | 1.37M |
| Asset Turnover | - | - | - |
| Asset Growth % | - | 75.02% | 1320.41% |
| Total Current Liabilities | 3.76M | 6.54M | 4.08M |
| Accounts Payable | 2.99M | 4.62M | 1.9M |
| Days Payables Outstanding | - | - | - |
| Short-Term Debt | 540.43K | 1.27M | 2.19M |
| Deferred Revenue (Current) | 0 | 0 | 0 |
| Other Current Liabilities | 221.88K | 645.95K | 0 |
| Current Ratio | 0.01x | 0.01x | 0.34x |
| Quick Ratio | 0.01x | 0.01x | 0.34x |
| Cash Conversion Cycle | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 |
| Total Liabilities | 3.76M | 6.54M | 4.08M |
| Total Debt | 540.43K | 1.27M | 2.19M |
| Net Debt | 485.36K | 1.17M | 1.67M |
| Debt / Equity | - | - | - |
| Debt / EBITDA | - | - | - |
| Net Debt / EBITDA | - | - | - |
| Interest Coverage | -16.51x | -13.23x | -9.63x |
| Total Equity | -3.71M | -6.44M | -2.71M |
| Equity Growth % | - | -73.87% | 57.89% |
| Book Value per Share | -6.43 | -11.17 | -4.62 |
| Total Shareholders' Equity | -3.71M | -6.44M | -2.71M |
| Common Stock | 111 | 391 | 613 |
| Retained Earnings | -6.14M | -13.52M | -21.47M |
| Treasury Stock | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Cash from Operations | -1.57M | -981.03K | -5.79M |
| Operating CF Margin % | - | - | - |
| Operating CF Growth % | - | 37.4% | -490.45% |
| Net Income | -2.46M | -7.38M | -7.96M |
| Depreciation & Amortization | 0 | 0 | 0 |
| Stock-Based Compensation | 110.15K | 1.73M | 1.8M |
| Deferred Taxes | 0 | 0 | 0 |
| Other Non-Cash Items | 140.43K | 2.62M | 328.93K |
| Working Capital Changes | 640.86K | 2.05M | 34.63K |
| Change in Receivables | 0 | 0 | -45.79K |
| Change in Inventory | 0 | 0 | 0 |
| Change in Payables | 413.6K | 1.63M | 1.18M |
| Cash from Investing | 0 | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - |
| Acquisitions | 0 | 0 | 0 |
| Investments | - | - | - |
| Other Investing | 0 | 0 | 0 |
| Cash from Financing | 1.62M | 1.02M | 6.21M |
| Debt Issued (Net) | 400K | 766.94K | 321.43K |
| Equity Issued (Net) | 0 | 255.41K | 1000K |
| Dividends Paid | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | -166.51K |
| Other Financing | 1.22M | 0 | 0 |
| Net Change in Cash | 55.07K | 41.32K | 417.05K |
| Free Cash Flow | -1.57M | -981.03K | -5.79M |
| FCF Margin % | - | - | - |
| FCF Growth % | - | 37.4% | -490.45% |
| FCF per Share | -2.72 | -1.70 | -9.86 |
| FCF Conversion (FCF/Net Income) | 0.64x | 0.13x | 0.73x |
| Interest Paid | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Interest Coverage | -16.51x | -13.23x | -9.63x |
| FCF Conversion | 0.64x | 0.13x | 0.73x |
Explore detailed financial history, valuation models, and returns analysis
DCF models, peer multiples & analyst estimates
Historical returns with dividends reinvested
Yield, growth, payout safety & DRIP calculator
EPS trends, net income & profitability analysis
Long-term charts & historical price data
Sales growth patterns & revenue breakdown
30 years of valuation, profitability & efficiency metrics